The test is the first offered for the Sgx Clarity system, a fully automated in vitro diagnostic platform leveraging single-molecule counting technology.
Separate studies in NEJM from Regeneron Pharmaceuticals and Ionis Pharmaceuticals target the ANGPTL3 gene in an effort to develop heart disease treatments.
The team performed a gene expression analysis to discover the new loci, bringing the total number of known risk loci associated with CAD to 73.
A pair of studies also uncovered atrial fibrillation risk loci specific to East Asian populations, particularly near SH3PXD2A.
The firm also plans to list its cardiac troponin I assay as CE marked and plans to submit data to the FDA for clearance of its Clarity system and assay in 2018.
The automated immunodiagnostics system is based on Singulex's single molecule counting technology.
The firm has settled on a set of metabolite biomarkers, along with an algorithm, for its first version of a test for arterial plaque buildup.
Investigators intend to genotype the biorepository using Illumina arrays with the aim of identifying markers that can be used to inform treatment and prevention efforts.
Looking at 927 patients undergoing coronary angiography, the researchers identified a four-protein panel that outperformed traditional clinical measures.
An exome-wide association study involving almost 2,800 individuals with dilated cardiomyopathy led to six new and two known susceptibility loci.
The company plans to open a $20 million Series C round in Q2 of this year and launch a study to support a US Food and Drug Administration submission in mid-2018.
The study will involve assaying proteomic markers for dementias including Alzheimer's disease, and understanding genomic markers as part of the normal aging process.
The researchers believe that by monitoring mtDNA copy number in blood, they will be able to identify people at risk for developing CHD who could benefit from preventative efforts.
A number of these loci were linked to blood pressure medication targets, and the researchers developed a genetic risk score.
Multi-omics, mass spec-based imaging, and cardiovascular biomarkers received extra attention at MSACL US while small molecules continue to drive the field.
Singulex's CEO provided an update at the JP Morgan Healthcare conference on the firm's progress in developing its immunodiagnostics platform.
The company will develop a data warehouse that integrates whole-genome sequence, medical, and wearables data from patients and controls.
By studying variants in PCSK9, researchers reported the therapies targeting the gene would have some of the same effects as statins.
In a new AMP working group project, labs can volunteer to compare their interpretation of challenging variants to help identify where and how the guidelines might be improved.
An international team of researchers examined genetic and lifestyle factors linked to heart disease in some 55,600 people.
The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.
Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.
In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.
The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.